Suppr超能文献

坦索罗辛能强有力且有选择性地拮抗人重组α(1A/1D)-肾上腺素能受体:与α(1A)-肾上腺素能受体缓慢解离可能是其对α(1A)-肾上腺素能受体亚型选择性的原因。

Tamsulosin potently and selectively antagonizes human recombinant α(1A/1D)-adrenoceptors: slow dissociation from the α(1A)-adrenoceptor may account for selectivity for α(1A)-adrenoceptor over α(1B)-adrenoceptor subtype.

机构信息

Applied Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc, Miyukigaoka, Tsukuba, Ibaraki 305–8585, Japan.

出版信息

Biol Pharm Bull. 2012;35(1):72-7. doi: 10.1248/bpb.35.72.

Abstract

We determined the binding affinity of tamsulosin, a selective α(1)-adrenoceptor antagonist, for human α(1)-adrenoceptor subtypes in comparison with those of other α(1)-adrenoceptor antagonists including silodosin, prazosin, 5-methylurapidil, terazosin, alfuzosin, nafopidil, urapidil and BMY7378. The association and dissociation kinetics of [(3)H]tamsulosin for recombinant human α(1)-adrenoceptor subtypes were compared with those of [(3)H]prazosin. Tamsulosin competitively inhibited [(3)H]prazosin binding to human α(1A)-, α(1B)- and α(1D)-adrenoceptors (pK(i) values were 10.38, 9.33, 9.85) indicating 11 and 3.4-fold higher affinities for human α(1A)-adrenoceptor than those for α(1B)- and α(1D)-adrenoceptors, respectively. The affinity of tamsulosin for the human α(1A)-adrenoceptor was, respectively, 5, 9.9, 38, 120, 280, 400, 1200 and 10000 fold higher than those of silodosin, prazosin, 5-methylurapidil, terazosin, alfuzosin, naftopidil, urapidil and BMY7378, respectively. [(3)H]Tamsulosin dissociated from the α(1A)-adrenoceptor slower than from the α(1B)- and α(1D)-adrenoceptors (α(1B)>α(1D)>α(1A)). Moreover, [(3)H]tamsulosin dissociated slower than [(3)H]prazosin from the α(1A)-adrenoceptor and faster from the α(1B)- and α(1D)-adrenoceptors. In conclusion, tamsulosin potently and selectively antagonized α(1A/1D)-adrenoceptor ligand binding, and slowly dissociated from the α(1A)-adrenoceptor subtype.

摘要

我们测定了坦索罗辛(一种选择性的α1-肾上腺素能受体拮抗剂)与其他α1-肾上腺素能受体拮抗剂(如西洛多辛、哌唑嗪、5-甲基育亨宾、特拉唑嗪、阿夫唑嗪、那氟沙星、乌洛他定和 BMY7378)对人α1-肾上腺素能受体亚型的亲和力,并进行了比较。我们比较了 [3H]坦索罗辛与 [3H]哌唑嗪与重组人α1-肾上腺素能受体亚型的结合和解离动力学。坦索罗辛竞争性地抑制了 [3H]哌唑嗪与人类α1A-、α1B-和α1D-肾上腺素受体的结合(pK i值分别为 10.38、9.33 和 9.85),表明其对人类α1A-肾上腺素能受体的亲和力比α1B-和α1D-肾上腺素能受体分别高 11 倍和 3.4 倍。坦索罗辛对人α1A-肾上腺素能受体的亲和力分别比西洛多辛、哌唑嗪、5-甲基育亨宾、特拉唑嗪、阿夫唑嗪、那氟沙星、乌洛他定和 BMY7378高 5、9.9、38、120、280、400、1200 和 10000 倍。[3H]坦索罗辛从α1A-肾上腺素能受体的解离速度比从α1B-和α1D-肾上腺素能受体(α1B>α1D>α1A)的解离速度慢。此外,与α1A-肾上腺素能受体相比,[3H]坦索罗辛从α1B-和α1D-肾上腺素能受体的解离速度更快。总之,坦索罗辛对α1A/1D-肾上腺素能受体配体结合具有强大的选择性拮抗作用,且从α1A-肾上腺素能受体亚型缓慢解离。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验